Blog

Mint Medical announces mint Lesion 3.5

Structured Reporting in Radiology can set a new bar in quality, completeness, and visual appeal of radiological reports. With structured reporting, you also have a rich data source for research, Artificial Intelligence learning, and evidence-based clinical decision support.

 

Traditionally, there is a separation of the radiological viewing application, reporting software, potential guidelines, and further context. With mint LesionTM 3.5, we integrate the image assessment with our proprietary, AI-driven workflow engine, allowing for a streamlined collection of structured data directly on the radiological image. The actual reporting of all pathological and other critical findings is performed automatically and integrates seamlessly into your reporting solution. mint LesionTM 3.5 features speech recognition with a direct speech to structured data technology, enabling thus, a simpler-than-ever  interaction with reporting software and classification of findings.

 

Data comes alive only when utilized appropriately and interpreted intelligently. In mint LesionTM 3.5, we have completely redesigned how complex clinical guidelines and clinical trial criteria work hand in hand with structured reporting templates. Not only is it easier than ever to model new guidelines in mint LesionTM; the underlying AI now completes data entries automatically, draws conclusions, and guides the user through less obvious but crucial aspects of the read. mint ReadAssist® technology makes results driven by AI transparent and reproducible.

 

We understand our users’ needs for Structured Reporting in Radiology that allows for standardization and is also capable of capturing the special needs of particular referrals or dedicated clinical research projects. Hence, mint LesionTM 3.5 comes with an intuitive and integrated Template Editor that allows you to create your own Structured Reporting templates, customize existing templates, as well as share and exchange templates with other users within clinical routine and clinical research. Team up your resources this way and assure standardized processes and data when obtaining evidence for tomorrow’s Radiology!

 

Annotations and measurements performed with conventional image viewing applications often get lost and are usually not organized in PACS so that they reflect a wider diagnostic context or treatment courses. We consider every drawn contour on a medical image as a data element of crucial value. mint LesionTM 3.5 underlines this with a new Radiomics Engine that collects data in unparalleled comprehension and depth. It may either unobtrusively run in the background, automatically collecting first, second, and higher order statistics for every 2D ROI or volumetric measurement. Alternatively, you can dig into radiomics data directly from within the mint LesionTM User Interface, or by means of our web-based mint AnalyticsTM module for visual and intuitive data exploration.

 

Radiomics data is put into a broader context by Structured Reporting within mint LesionTM and we at Mint Medical continuously strive to expand our technological leadership in this field. Over the years, a continuous evolution of reading profiles within mint LesionTM has led us to provide the most comprehensive and detailed data models within Oncologic Radiology. With mint LesionTM 3.5, we update existing reading profiles and introduce many new ones. All reading profiles are implemented considering established lexica and ontologies such as RadLex®.

Among the improvements on the reading profiles are:

 

 

New Reading Profiles in mint Lesion 3.4.4 and mint Lesion 3.5

 

Screening and Staging:

 

  • Esophagus / Stomach Cancer (TNM 8)
  • Urological Cancers (TNM 8)
  • Cervix / Endometrium Cancer (TNM 8 and FIGO)
  • Oral Cavity, Lip, and refined Larynx / Pharynx Cancer (TNM 8)
  • Rectum Cancer (ESGAR Guidelines)
  • Lung Cancer Screening following ACR® Lung-RADS and Fleischner Society Guideline
  • HCC surveillance following ACR® LI-RADS
  • Multiple Myeloma
  • Refined Pediatric Cancer Staging and therapy response: Neuroblastoma, Nephroblastoma, PRETEXT/POSTEXT, Rhabdomyosarcoma
  • Prostate Cancer Bone Disease following MET-RADS-P

 

 

Therapy response assessment:

 

  • imRECIST (Immunotherapy)
  • RANO-BM (Brain Metastases)
  • LYRIC (Lymphoma Immunotherapy)
  • RECIL 2017 (Lymphoma)
  • PERCIST (PET Imaging)
  • PCWG3 (Prostate Cancer) for Bone Disease
  • iwCLL Criteria for Chronic Lymphocytic Leukemia (Hallek)

 

 

Back